ClinicalTrials.gg
Not yet recruitingNCT07732348Updated Sep 30, 2026

Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)

An interventional study of Ganirelix ; Cetrorelix and Medroxyprogesterone Acetate ; Micronized Progesterone in Infertility, Female and Ovulation Induction, sponsored by Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita). Not yet recruiting. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Not applicable, Interventional, and Treatment

How we know

Updated Sep 30, 2026Enrollment updatedEligibility revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Study summary

Women undergoing IVF/ICSI who are candidates for a GnRH-antagonist protocol are randomly assigned 1:1 to oral linzagolix or the standard injectable GnRH antagonist (ganirelix or cetrorelix). A third, non-randomized group of women with a clinical indication for progestin-primed ovarian stimulation (PPOS) - for example, a need for a freeze-all strategy - is enrolled concurrently as a comparator cohort. The randomized comparison (linzagolix vs. injectable antagonist) is the primary, non-inferiority analysis; the PPOS cohort provides an exploratory, non-randomized comparison, analyzed with adjustment for baseline differences.

Read the detailed description

This is a single-center, prospective, randomized, controlled non-inferiority trial with a concurrent non-randomized comparator cohort, conducted at CENTRO AMBRA. Women eligible for a GnRH-antagonist protocol are randomized 1:1 to oral linzagolix or the injectable GnRH antagonist using a computer-generated permuted-block randomization sequence (block size of 4, no stratification); allocation is concealed until treatment initiation. A separate, concurrent cohort of women with a clinical indication for PPOS is enrolled as a non-randomized comparator; because assignment to this cohort reflects clinical criteria, it may differ systematically from the randomized arms - confounding by indication limited to the PPOS comparison. This is addressed through pre-specified multivariable adjustment and, where sample size permits, propensity-score methods; the PPOS comparison is interpreted as an association, the randomized comparison as supporting non-inferiority. As treatment is known to investigators and patients, there is no masking (open-label); oocyte and embryo assessment follows standardized, predefined procedures. A target of 40 participants per group (120 total) was defined based on the pre-specified non-inferiority margin of 2.0 MII oocytes. All participants undergo a routine clinical follow-up visit 5 days after oocyte pick-up."

02

Conditions studied

  • Infertility, Female
  • Ovulation Induction

Browse trials for

Keywords

  • Oral GnRH Antagonist
  • Linzagolix
  • Controlled Ovarian Stimulation
  • In Vitro Fertilization
  • ICSI
  • Progestin-Primed Ovarian Stimulation
  • Oocyte Maturation
  • OHSS Prevention
03

In context

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

This study's planned enrollment of 120 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female, aged 18 to 42 years
  • Indication for IVF/ICSI with controlled ovarian stimulation at CENTRO AMBRA
  • Population unselected for ovarian reserve (normal, poor, and high responders are eligible)
  • Written , including consent for off-label use of linzagolix and for data processing
  • For the two antagonist arms (Linzagolix and Injectable GnRH Antagonist): acceptance of randomization

Exclusion criteria

Exclusion Criteria:

  • Known or to the study drugs
  • Uterine pathology relevant to the study outcome (e.g., uterine malformations, significant submucosal fibroids)
  • Contraindications to pregnancy or to ovarian stimulation
  • Concurrent participation in another interfering interventional study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    B - Injectable GnRH Antagonist (Ganirelix/Cetrorelix)

    Drug: Ganirelix ; Cetrorelix

  • Active comparator
    C - PPOS (Progestin-Primed Ovarian Stimulation) Cohort

    Drug: Medroxyprogesterone Acetate ; Micronized Progesterone

  • Experimental
    A - Linzagolix

    Drug: Linzagolix

Interventions

  • DrugGanirelix ; Cetrorelix

    Drug pages: GanirelixStudies of GanirelixGanirelix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CetrorelixStudies of CetrorelixCetrorelix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ganirelix Type: Drug Group: B Description: Ganirelix acetate 0.25 mg administered by daily subcutaneous injection, per fixed or flexible protocol according to center practice, to suppress the premature LH surge during controlled ovarian stimulation. Cetrorelix Type: Drug Arm: B Description: Cetrorelix acetate 0.25 mg administered by daily subcutaneous injection, per fixed or flexible protocol according to center practice, to suppress the premature LH surge during controlled ovarian stimulation.

  • DrugMedroxyprogesterone Acetate ; Micronized Progesterone

    Drug pages: Medroxyprogesterone AcetateStudies of Medroxyprogesterone AcetateMedroxyprogesterone Acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ProgesteroneStudies of ProgesteroneProgesterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is a non-randomized, concurrently enrolled comparator cohort (not part of the 1:1 randomization). Medroxyprogesterone Acetate - Type: Drug - Arm: C - Description: Medroxyprogesterone acetate 10 mg/day administered orally from stimulation day 1-2 through the day of trigger, as part of a progestin-primed ovarian stimulation (PPOS) protocol with mandatory freeze-all strategy. Micronized Progesterone - Type: Drug - Arm: C - Description: Micronized progesterone 100-200 mg/day administered orally from stimulation day 1-2 through the day of trigger, as part of a progestin-primed ovarian stimulation (PPOS) protocol with mandatory freeze-all strategy.

  • Description: Linzagolix Type: Drug Group: A Description: Linzagolix 200 mg administered orally once daily, started per center protocol (fixed stimulation day or upon appearance of the dominant follicle) and continued through the day of trigger. Investigational off-label use for suppression of the premature LH surge during controlled ovarian stimulation.

06

What researchers measure

Primary outcomes

  1. Number of Mature (MII) Oocytes Retrieved

    Number of metaphase II (mature) oocytes collected at oocyte retrieval. Non-inferiority of linzagolix versus the injectable GnRH antagonist will be concluded if the lower bound of the 95% confidence interval for the adjusted mean difference in MII oocytes (adjusted for ovarian reserve, age, BMI, gonadotropin type and dose, and trigger type) excludes a loss greater than the pre-specified non-inferiority margin of 2.0 MII oocytes. An exploratory comparison with the PPOS cohort is also performed, adjusted for baseline confounders.

    Time frame: At oocyte retrieval, approximately 36 hours after trigger (first study cycle)

Secondary outcomes

  1. Incidence of Premature LH Rise

    Time frame: From initiation of LH-suppressive treatment to the day of trigger (up to approximately 12 days)

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 3 months is below that.

Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 28, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
195→120
Sep 30, 2026
Eligibility
Revised
Sep 30, 2026
Interventions
Changed Medroxyprogesterone Acetate ; Dienogest ; Micronized Progesterone→Medroxyprogesterone Acetate ; Micronized Progesterone
Sep 30, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionNumber of Mature (MII) Oocytes Retrieved: how it is measured was reworded
Sep 30, 2026
Title
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for inIn Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Prospective Comparative Observational StudyConcurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)
Sep 30, 2026
Design
Study type Observational→Interventional
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Enrollment 195→120
    Eligibility Revised
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionNumber of Mature (MII) Oocytes Retrieved: how it is measured was reworded
    Interventions Changed Medroxyprogesterone Acetate ; Dienogest ; Micronized Progesterone→Medroxyprogesterone Acetate ; Micronized Progesterone
    Design Study type Observational→Interventional
    Title Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist and Progestin-primed Ovarian Stimulation (PPOS) in Controlled Ovarian Stimulation for inIn Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Prospective Comparative Observational StudyConcurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07732348
Lead sponsor
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion